429 related articles for article (PubMed ID: 23990795)
1. The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.
Benitez BA; Karch CM; Cai Y; Jin SC; Cooper B; Carrell D; Bertelsen S; Chibnik L; Schneider JA; Bennett DA; ; ; Fagan AM; Holtzman D; Morris JC; Goate AM; Cruchaga C
PLoS Genet; 2013; 9(8):e1003685. PubMed ID: 23990795
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
3. Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease.
Nho K; Horgusluoglu E; Kim S; Risacher SL; Kim D; Foroud T; Aisen PS; Petersen RC; Jack CR; Shaw LM; Trojanowski JQ; Weiner MW; Green RC; Toga AW; Saykin AJ;
BMC Med Genomics; 2016 Aug; 9 Suppl 1(Suppl 1):30. PubMed ID: 27535542
[TBL] [Abstract][Full Text] [Related]
4. Presenilin E318G variant and Alzheimer's disease risk: the Cache County study.
Hippen AA; Ebbert MT; Norton MC; Tschanz JT; Munger RG; Corcoran CD; Kauwe JS
BMC Genomics; 2016 Jun; 17 Suppl 3(Suppl 3):438. PubMed ID: 27357204
[TBL] [Abstract][Full Text] [Related]
5. Amyloid-β
Perrone F; Bjerke M; Hens E; Sieben A; Timmers M; De Roeck A; Vandenberghe R; Sleegers K; Martin JJ; De Deyn PP; Engelborghs S; van der Zee J; Van Broeckhoven C; Cacace R;
Alzheimers Res Ther; 2020 Sep; 12(1):108. PubMed ID: 32917274
[TBL] [Abstract][Full Text] [Related]
6. The
Almkvist O; Graff C
Genes (Basel); 2021 Dec; 12(12):. PubMed ID: 34946903
[TBL] [Abstract][Full Text] [Related]
7. Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer's disease in a Family with Late-onset Dementia.
Artuso V; Benussi L; Ghidoni R; Moradi-Bachiller S; Fusco F; Curtolo S; Roiter I; Forloni G; Albani D
Curr Alzheimer Res; 2019; 16(1):1-7. PubMed ID: 30381075
[TBL] [Abstract][Full Text] [Related]
8. Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations.
Lautner R; Insel PS; Skillbäck T; Olsson B; Landén M; Frisoni GB; Herukka SK; Hampel H; Wallin A; Minthon L; Hansson O; Blennow K; Mattsson N; Zetterberg H
Alzheimers Res Ther; 2017 Oct; 9(1):87. PubMed ID: 29061195
[TBL] [Abstract][Full Text] [Related]
9. APOE ε4 influences cognitive decline positively in APP and negatively in PSEN1 mutation carriers with autosomal-dominant Alzheimer's disease.
Almkvist O; Johansson C; Laffita-Mesa J; Thordardottir S; Graff C
Eur J Neurol; 2022 Dec; 29(12):3580-3589. PubMed ID: 36039401
[TBL] [Abstract][Full Text] [Related]
10. Association of Apolipoprotein E ε4 With Transactive Response DNA-Binding Protein 43.
Wennberg AM; Tosakulwong N; Lesnick TG; Murray ME; Whitwell JL; Liesinger AM; Petrucelli L; Boeve BF; Parisi JE; Knopman DS; Petersen RC; Dickson DW; Josephs KA
JAMA Neurol; 2018 Nov; 75(11):1347-1354. PubMed ID: 30422173
[TBL] [Abstract][Full Text] [Related]
11. The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease.
Bonham LW; Desikan RS; Yokoyama JS;
Acta Neuropathol Commun; 2016 Jun; 4(1):65. PubMed ID: 27357286
[TBL] [Abstract][Full Text] [Related]
12. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.
Balasa M; Vidal-Piñeiro D; Lladó A; Antonell A; Bosch B; Castellanos F; Bargalló N; Bartres-Faz D; Molinuevo JL; Sánchez-Valle R
J Alzheimers Dis; 2012; 30(3):605-16. PubMed ID: 22426017
[TBL] [Abstract][Full Text] [Related]
13. CSF Aβ
Lim YY; Yassi N; Bransby L; Ayton S; Buckley RF; Eratne D; Velakoulis D; Li QX; Fowler C; Masters CL; Maruff P
Neurobiol Aging; 2023 Sep; 129():209-218. PubMed ID: 37399739
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in CSF biomarkers vary by Alzheimer disease stage and
Babapour Mofrad R; Tijms BM; Scheltens P; Barkhof F; van der Flier WM; Sikkes SAM; Teunissen CE
Neurology; 2020 Oct; 95(17):e2378-e2388. PubMed ID: 32788242
[TBL] [Abstract][Full Text] [Related]
15. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.
Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Shaw LM; Trojanowski JQ; Aisen PS; Weiner M; Petersen RC; Jack CR;
Ann Neurol; 2010 Mar; 67(3):308-16. PubMed ID: 20373342
[TBL] [Abstract][Full Text] [Related]
16. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
[TBL] [Abstract][Full Text] [Related]
17. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
18. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
[TBL] [Abstract][Full Text] [Related]
19. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families.
Cruchaga C; Haller G; Chakraverty S; Mayo K; Vallania FL; Mitra RD; Faber K; Williamson J; Bird T; Diaz-Arrastia R; Foroud TM; Boeve BF; Graff-Radford NR; St Jean P; Lawson M; Ehm MG; Mayeux R; Goate AM;
PLoS One; 2012; 7(2):e31039. PubMed ID: 22312439
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
